Effects of CPAP on Diet, Physical Activity, and Cardiovascular Risk
|Study Design:||Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||Effects of CPAP on Diet, Physical Activity, and Cardiovascular Risk|
- Change from baseline physical activity at 2 months [ Time Frame: At baseline and after 2 months of treatment ]Free-living physical activity will be measured via actigraphy at baseline preceding treatment phase, and at the end of treatment phase.
- Change from baseline ad libitum food intake at 2 months [ Time Frame: At baseline and after 2 months of treatment ]Participants will be served meals (breakfast, lunch, dinner, snack) at specified times, but food will be served in excess such that participants will be able to eat as much as they want.
- Change from baseline appetite-regulating hormones and cardiovascular risk factors at 2 months [ Time Frame: At baseline and after 2 months of treatment ]Blood will be sampled once in the morning in the fasted state to assay levels of circulating hormones that regulate appetite and hunger, including leptin, ghrelin, adiponectin, and glucagon-like peptide-1, as well as inflammatory and cardiovascular risk markers
|Study Start Date:||May 2015|
|Estimated Study Completion Date:||March 2018|
|Estimated Primary Completion Date:||March 2018 (Final data collection date for primary outcome measure)|
Experimental: Active CPAP
Active CPAP will be a therapeutic dose of positive airway pressure each night for 2 months
Device: Active CPAP
Active CPAP will be a therapeutic dose CPAP each night for 2 months
This study investigates the effects of 2 mo of continuous positive airway pressure (CPAP) on physical activity, energy intake (EI), and cardiovascular risk factors in overweight/obese patients with moderate-to-severe obstructive sleep apnea (OSA) and excessive daytime sleepiness (EDS). Following pre-experimental baseline measures, patients will be instructed to use CPAP at home each night throughout the 2 mo treatment phase. Before and after the 2 mo treatment phase, patients will undergo a 1-d in-lab testing period at the Clinical Research Resource (CRR) at Columbia University Medical Center. Upon completion of the laboratory phase 1, patients will return home for a 2 mo treatment period, followed by the second tracking period including laboratory visit 2.
At the conclusion of the 2 mo treatment phase, patients will enter the laboratory at the Columbia University Medical Center for a 1-d period. Patients will arrive at ~0800 h and will remain in the laboratory for the following 24 h. Blood will be sampled in the fasting state in the morning, and will be assayed for select appetite-regulating hormones (leptin, ghrelin, adiponectin, glucagon-like peptide-1). We will al,so assess body composition. During the laboratory day, ad libitum EI will be measured for each treatment phase. Breakfast, lunch, snack, and dinner will be served at the standard times, but each meal item will be served in excess such that patients will be able to eat as much or as little of each food as they choose. Additional snack choices will also be freely available during the wake episode.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01944020
|Contact: Ari Shechter, Ph.D.||(212) firstname.lastname@example.org|
|United States, New York|
|Columbia University Medical Center||Recruiting|
|New York, New York, United States, 10032|
|Contact: Ari Shechter, Ph.D. 212-851-5584 email@example.com|
|Principal Investigator: Ari Shechter, Ph.D.|
|Principal Investigator:||Ari Shechter, Ph.D.||New York Obesity Research Center, Columbia University|